Company Profile · Healthcare

Bachem Holding AG

BANB · SW
Country
Switzerland
Employees
2,130
Buffett Score
59/100
Medium
Market capCHF 5.4B
Revenue (TTM)CHF 695.07M
EBITDACHF 210.76M
Profit margin21.41%
ROE10.44%
P/E (TTM)36.41
Forward P/E29.85
PEG0.61
EPSCHF 1.98
Dividend yield1.24%
52-week rangeCHF 48.22 – CHF 83.25

Data from EODHD, shown in the reporting currency; for reference only, not investment advice.

Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. Bachem Holding AG was incorporated in 1971 and is headquartered in Bubendorf, Switzerland. Bachem Holding AG operates as a subsidiary of Ingro Finanz AG.

History

Coming soonThis section is being filled in — check back soon.

Industry position

Coming soonThis section is being filled in — check back soon.

No reports on this stock in your language yet.